Onkologie, Hämatologie - Daten und Informationen

Literatur zu Kapitel 3.7: Molekulare Marker

Autor/en: U.R. Hengge, S. Nambiar, M. Hassan, A. Marini, A. Gustrau, A. Mirmohammadsadegh
Letzte Änderung: 01.11.2007
  • Alonso SR et al.
    Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study.
    Am J Pathol 2004;164:193-203.

  • Baylin SB, Herman JG.
    DNA hypermethylation in tumorigenesis: epigenetics joins genetics.
    Trends Genet 2000;16:168-174.

  • Berger AJ et al.
    Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.
    Cancer Res 2003;63:8103-8107.

  • Bernard K et al.
    Functional proteomic analysis of melanoma progression.
    Cancer Res 2003;63:6716-6725.

  • Bittner M et al.
    Molecular classification of cutaneous malignant melanoma by gene expression profiling.
    Nature 2000;406:536-540.

  • Carta F et al.
    Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases.
    Melanoma Res 2005;15:235-244.

  • Clark EA et al.
    Genomic analysis of metastasis reveals an essential role for RhoC.
    Nature 2000;406:532-535.

  • Davies H et al.
    Mutations of the BRAF gene in human cancer.
    Nature 2002;417:949-954.

  • Fujiwara Y et al.
    Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients.
    Cancer Res 1999;59:1567-1571.

  • Furuta J et al.
    Promoter methylation profiling of 30 genes in human malignant melanoma.
    Cancer Sci 2004;95:962-968.

  • Garraway LA et al.
    Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
    Nature 2005;436:117-122.

  • Giese T et al.
    Quantification of melanoma micrometastases in sentinel lymph nodes using real-time RT-PCR.
    J Invest Dermatol 2005;124:633-637.

  • Hoon DS et al.
    Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.
    Oncogene 2004;23:4014-4022.

  • Howell WM et al.
    Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma.
    Eur J Immunogenet 2003;30:409-414.

  • Kammula US et al.
    Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction - staged sentinel lymph nodes from melanoma patients.
    J Clin Oncol 2004;22:3989-3996.

  • King R et al.
    Microphthalmia transcription factor. A sensitive and specific melanocyte marker for melanoma diagnosis.
    Am J Pathol 1999;155:731-738.

  • Kuo CT et al.
    Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes.
    J Clin Oncol 2003;21:3566-3572.

  • Kuo CT et al.
    Assessment of messenger RNA of beta 1-4-N-acetylgalactosaminyl-transferase as a molecular marker for metastatic melanoma.
    Clin Cancer Res 1998;4:411-418.

  • Lee JH et al.
    Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes.
    Clin Cancer Res 2005;11:107-112.

  • Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR.
    Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma.
    J Invest Dermatol 2006; Feb;126(2):422-31. PM:16374457

  • Maschhoff KL, Baldwin HS.
    Molecular determinants of neural crest migration.
    Am J Med Genet 2000;97:280-288.

  • McGill GG et al.
    Bcl-2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability.
    Cell 2002;109:707-718.

  • Murphy PM.
    Chemokines and the molecular basis of cancer metastasis.
    N Engl J Med 2001;345:833-835.

  • Nambiar S et al.
    Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays.
    Arch Dermatol 2005;141:165-173.

  • Palmieri G et al.
    Polymerase chain reactionbased detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group.
    J Clin Oncol 1999;17:304-311.

  • Ranieri JM et al.
    Lack of prognostic importance of reverse-transcriptase polymerase chain reaction detection of circulating messenger RNA in patients with melanoma.
    Plast Reconstr Surg 2005;115:1058-1063.

  • Robledo MM et al.
    Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells.
    J Biol Chem 2001;276:45098-105.

  • Scala S et al.
    Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
    Clin Cancer Res 2005;11:1835-1841.

  • Spugnardi M et al.
    Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
    Cancer Res 2003;63:1639-1643.

  • Takeuchi H et al.
    CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells.
    Clin Cancer Res 2004a;10:2351-2358.

  • Takeuchi H et al.
    Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients.
    J Clin Oncol 2004b;22:2671-2680.

  • Takeuchi H et al.
    Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas.
    Cancer Res 2003;63:441-448.

  • Ulrich J et al.
    Prognostic significance of detecting micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies: lessons from 322 consecutive melanoma patients.
    Eur J Cancer 2004;40:2812-2819.

  • Voit C et al.
    Molecular staging in stage II and III melanoma patients and its effect on long-term survival.
    J Clin Oncol 2005;23:1218-1227.

  • Weeraratna AT et al.
    Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma.
    Cancer Cell 2002;1:279-288.

  • Widschwendter M, Jones PA.
    DNA methylation and breast carcinogenesis.
    Oncogene 2002;21:5462-5482.

  • Wilson LL et al.
    Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry.
    Ann NY Acad Sci 2004;1022:317-322.

Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"; Publikation als Buch: Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch: